On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half…
Q2 Revenues of $28.8 millionQ2 GAAP operating income $0.8 million, adjusted operating income $3.6 millionStrong H1 operating cash flow drove…
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost…
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2…
Development Advisory Committee strengthened with the expertise and leadership of Dr. YavariTORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) --…
Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a…
Revenue optimization and compliance leader included in Fortune’s 2023 Best Workplaces for Millennials listSAN MATEO, Calif.--(BUSINESS WIRE)--Fortune Media and Great…
A significant proportion of patients undergoing cancer therapy experience diarrhea, which has the potential to cause dehydration and non-adherence to…
Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated…
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development…